Novartis Moving COPD Antagonist Into Phase III Trials, Triggering Milestones For Sosei
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Novartis' muscarinic antagonist NVA237 for treating chronic obstructive pulmonary disease is slated to enter Phase III clinical trials in the United States and the European Union in the second half of this year, according to a joint announcement by Japanese biopharmaceutical start-up Sosei Group and the U.K.'s Vectura Group